Trying to sort facts from fiction in the world of stocks
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like .42 was bottom..Bounce!
Someone post what he says please..
Trying to push the .16 bigtime....Good breakout could be coming.
Looking good here, EEE should see major moves up over the next week or two...IMO
ESPH gets oil clean up contract!
http://ih.advfn.com/p.php?pid=nmona&article=43097201&symbol=NB%5EESPH
Zero Bid Soon Boys..IMO
Oil headed for Florida 9 mi out from coast, I am sure Florida is getting ready for clean-up and won't wait for BP..I just can't believe nobody has put this company under a contract yet for clean-up.
This could be a monster in the coming days with a contract announcement.
Don't they have just 1 oil seperator? their main business is gas wells.
Ecosphere Technologies, Inc. is a diversified water engineering and services company primarily focused on the natural gas industry. The Company provides water recycling services at the well site to provide clean water for energy companies to extract natural gas from unconventional shale plays.
Oil spill is not their main business....
PM looking good for an upswing today.
Looks like a great day to go to cash...lol
CLDX looking like rebound in PM.
Feels like the quite calm before a storm
CLDX PM looking good so far..
Great Bloomberg CLDX News article tonite
http://www.sfgate.com/cgi-bin/article.cgi?f=/g/a/2010/05/20/bloomberg1376-L2QNDI1A74E9-6.DTL
EXEL Businessweek article released tonite
http://www.businessweek.com/news/2010-05-20/exelixis-drugs-works-against-a-deadly-brain-cancer-in-a-study.html
Thanks guys...
Anybody buying CLDX at these levels?
Thanks $heff..Thinking about CLDX
Added EXEL....great price.
AGEN NEWS
Encouraging Data Presented on Oncophage® Vaccine at International Conference on Brain Tumor Research and Therapy
Antigenics (NASDAQ: AGEN) today announced that data from a multi-center Phase 1/2 clinical trial of Oncophage (vitespen) for recurrent high-grade glioma (brain cancer) was presented at the International Conference on Brain Tumor Research and Therapy. The study was conducted by the Brain Tumor Research Center at the University of California, San Francisco (UCSF).
Data from 32 evaluable patients suggest that vaccination with Oncophage may improve overall survival in patients with recurrent high-grade glioma. An overall median survival of 44 weeks after tumor resection was observed. Approximately 70% of the evaluable patients survived beyond 36 weeks, and 41% survived up to or longer than one year. This is considered a significant achievement in the treatment of recurrent high-grade glioma. In addition, Oncophage was well tolerated, with no serious adverse events attributable to the vaccine.
All patients tested to date exhibited a significant innate immune response following vaccine administration. Furthermore, the majority of these patients showed an adaptive immune response, demonstrated by significant increases in CD8 and CD4 T cell responses. An innate immune response is defined as a generalized response, whereas the adaptive immune response is tumor antigen-specific. Taken together, these immune responses have the potential to kill tumor cells and may lead to patient benefit.
“The results from this trial suggest clear biological activity associated with Oncophage treatment as evidenced by stimulation of robust immune responses in the patients evaluated to date,” said Andrew T. Parsa, MD, PhD, associate professor in the department of neurological surgery at UCSF, and principal investigator of the trial, who presented the update. “Furthermore, I am encouraged that recurrent glioma patients treated with Oncophage are experiencing longer than anticipated survival without treatment-related toxicities. These data could potentially justify advancement into late-stage trials.”
In a separate, more recently initiated Phase 2 trial enrolling patients with newly diagnosed glioma (n=8), there have been no significant toxicities associated with concurrent treatment of Oncophage and Temodar® (Merck: temozolomide), a chemotherapeutic that is the current standard of care. Clinical and immunologic evaluation is ongoing.
Study Details
The Phase 2 portion of the recurrent high-grade glioma trial is designed to enroll approximately 50 patients. The overall goal of this investigator-initiated, multi-center, single-arm, open-label study is to evaluate median overall survival, progression-free survival and immunologic response to vaccine treatment. Patients undergo surgery to remove their tumors, which are then used to manufacture their patient-specific vaccines. Patients receive four weekly doses of Oncophage and then bi-weekly doses thereafter in the absence of disease progression, unacceptable toxicity, or vaccine depletion. To date, side effects observed in this study have been minor and have included injection-site reaction, fatigue, and headaches. The trial is supported in part through a grant from the National Institutes of Health. Last year, the trial was expanded to include New York-Presbyterian Hospital/Columbia University Medical Center and the Brain Tumor and Neuro-Oncology Center at University Hospitals Case Medical Center.
The Phase 2 newly diagnosed glioma trial is designed to enroll about 60 patients. This single-arm, open-label, investigator-initiated trial is designed to evaluate median overall survival, progression-free survival and immunologic response to vaccine treatment. Patients undergo surgery to remove their tumors, which are then used to manufacture their patient-specific vaccines. According to the protocol, patients receive Temodar concurrently with Oncophage once weekly for four consecutive weeks and monthly until vaccine depletion. The trial is supported through a grant from the American Brain Tumor Association and the National Cancer Institute Special Programs of Research Excellence.
Antigenics will assess data from the glioma trials as it matures and is currently assessing potential product registration strategies for Oncophage in this indication in the US and other territories.
About Oncophage
Nearly 800 patients in clinical trials throughout North America and Europe have been treated with Oncophage produced in Antigenics’ commercial facility located in Lexington, Massachusetts. Studies with Oncophage have demonstrated efficacy signals in multiple cancers, including melanoma, glioma, colorectal, pancreatic, renal cell carcinoma, gastric cancer and non-Hodgkins lymphoma.
Oncophage is approved for sale in Russia for the adjuvant treatment of kidney cancer patients at intermediate-risk for disease recurrence.
Derived from each individual’s tumor, Oncophage contains the ‘antigenic fingerprint’ of the patient’s particular cancer and is designed to reprogram the body’s immune system to target only cancer cells bearing this fingerprint. Oncophage is intended to leave healthy tissue unaffected and limit the debilitating side effects typically associated with traditional cancer treatments such as chemotherapy and radiation therapy. Oncophage has been studied in Phase 3 clinical trials for the treatment of kidney cancer and metastatic melanoma and is currently being investigated in Phase 2 trials in recurrent and newly diagnosed glioma.
Oncophage has received fast track and orphan drug designations from the US Food and Drug Administration (FDA) for both kidney cancer and metastatic melanoma as well as orphan drug designation from the EMEA for kidney cancer. In 2009, Oncophage also received orphan drug designations from the FDA and EMEA for glioma.
In April 2009, the World Vaccine Congress named Oncophage as the best therapeutic vaccine.
About Brain and Spinal Cord Tumors
The American Cancer Society estimated that 22,070 malignant tumors of the brain or spinal cord would be diagnosed during 2009 in the United States, and that about 12,920 people would die from these tumors. Primary malignant brain tumors are uniformly fatal, and the five-year survival rate for the highest grade of malignant glial neoplasm, glioblastoma multiforme, is less than 2 percent. Brain and spinal cord tumors account for about 1 percent of all cancers and 2 percent of all cancer-related deaths.
About UCSF
UCSF is a leading university that consistently defines health care worldwide by conducting advanced biomedical research, educating graduate students in the life sciences, and providing complex patient care. For more information, please visit www.ucsf.edu.
Dr. Parsa has not received any financial support or travel expense reimbursement for this presentation or for consulting activities on behalf of Antigenics. Dr. Parsa does not have an equity interest in Antigenics or other financial relationship with the company.
About the American Brain Tumor Association
For more than 37 years, the American Brain Tumor Association has provided critical funding to researchers working toward breakthroughs in brain tumor diagnosis, treatment and care, with the ultimate goal of finding a cure. The ABTA is also the recognized resource for comprehensive information and compassionate support for the brain tumor patients, families and caregivers who are living with this disease.
IR screwed up and sent it out under APII only.Link
http://phx.corporate-ir.net/phoenix.zhtml?c=130431&p=irol-IRHome
NEWS-APP Pharmaceuticals has Over 30 Scientific Presentations at ASCO Exploring ABRAXANE's Expanded Potential in Multiple Difficult-to-Treat Cancers
http://phx.corporate-ir.net/phoenix.zhtml?c=130431&p=irol-newsArticle&ID=1428291&highlight
I would think this would be huge for APCVZ but it is not being PR'd under the APCVZ symbol, just ABII..
Thank You..
Anybody playing SNTS for June FDA Date? not much chat about this one..
Got a starter position here today, lets see what happens.
WOW! .10 cents! we are trucking now...Look out, this thing is flying...lol
Keep living the dream Pal...Everyone has been waiting months for that news and insiders are dumping shares..Who knows what will happen, but its not looking good.
Glad I got out at .14, I may jump back if it hits .05 again which looks like it will at this point.
cctc website down because they didn't pay the bill...lol.....God I hope not...GLTA
SNSS Vol 2,652,688 and running
SNSS going crazy!
SNSS going crazy!
Looks like a run coming..
SNSS .98 Vol coming in..
Great CC looks like partnership news coming along with official release of great study results on the 20th
Looking good for a huge breakout..
TODAY ! Antigenics to Webcast 2010 Annual Shareholders Meeting
Antigenics Inc. (NASDAQ: AGEN) invites investors and the general public to its 2010 Annual Shareholders Meeting at 5:00 p.m. ET on Wednesday, May 12. They may release the study data in the webcast followed by a official PR tommorrow...